Citadel Advisors Llc Decreased Coherus Biosciences Inc (Call) (NASDAQ:CHRS) Stake By $21.90 Million

August 13, 2018 - By Robert Reynolds

Coherus BioSciences, Inc. (NASDAQ:CHRS) LogoInvestors sentiment increased to 1.49 in Q1 2018. Its up 0.33, from 1.16 in 2017Q4. It is positive, as 10 investors sold CHRS shares while 27 reduced holdings. 21 funds opened positions while 34 raised stakes. 51.20 million shares or 4.31% more from 49.09 million shares in 2017Q4 were reported. Omers Administration invested in 0% or 23,400 shares. Deutsche Bancshares Ag owns 602,970 shares. Td Asset Management stated it has 16,271 shares or 0% of all its holdings. Price T Rowe Assocs Incorporated Md holds 0% or 1.49M shares. 11,925 are owned by Grp Inc One Trading Ltd Partnership. Principal Group Inc Inc owns 10,410 shares. Ameriprise Fincl Inc accumulated 412,455 shares or 0% of the stock. Millennium Mgmt stated it has 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). First Personal Financial holds 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 876 shares. Balyasny Asset Mngmt Ltd Liability Corporation has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Retail Bank Of America De reported 68,184 shares. Morgan Stanley reported 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Highbridge Capital Mgmt Ltd Llc owns 375,000 shares for 0.07% of their portfolio. Vanguard Group Inc Inc holds 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 2.06M shares. Highland Mgmt Lp has invested 0.2% in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Citadel Advisors Llc decreased its stake in Coherus Biosciences Inc (Call) (NASDAQ:CHRS) by 98.73% based on its latest 2018Q2 regulatory filing with the SEC. Citadel Advisors Llc sold 1.68M shares as the company’s stock rose 49.27% while stock markets declined. The hedge fund held 21,600 shares of the health care company at the end of 2018Q2, valued at $302,000, down from 1.71 million at the end of the previous reported quarter. Citadel Advisors Llc who had been investing in Coherus Biosciences Inc (Call) for a number of months, seems to be less bullish one the $1.26 billion market cap company. The stock increased 1.33% or $0.25 during the last trading session, reaching $19. About 338,764 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 24.26% since August 13, 2017 and is downtrending. It has underperformed by 36.83% the S&P500.

Citadel Advisors Llc, which manages about $202.23 billion US Long portfolio, upped its stake in Transocean Ltd (Put) (NYSE:RIG) by 2.03M shares to 2.69 million shares, valued at $36.21 million in 2018Q2, according to the filing. It also increased its holding in Boston Scientific Corp (NYSE:BSX) by 6.70M shares in the quarter, for a total of 6.85 million shares, and has risen its stake in Ishares Tr (IYG).

Ken Griffin career started in 1986 as a stocks and options trader. Soon he started a convertible bond arbitrage fund. When the market crashed in 1987, he was already rich. Today he is a billionire and manages and Citadel Investment Group is among the world’s largest hedge funds. In 2011 when many hedge funds and CTAs had poor returns, Citadel had returned over 20%, it also returned nearly 25% in 2012 and then 20+% in 2013. Citadel Advisors Llc is a Illinois-based hedge fund that was founded by Ken Griffin. It had more than $142.00 billion assets under management in December, 2014. Citadel Advisors Llc is the 30th largest hedge fund in our database. Taken from Citadel Advisors latest Adv, the fund reported to have 985 full and part-time employees. Among which 872 performing investment advisory and research functions. The hedge fund had between 11-25 clients.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Among 2 analysts covering Coherus Biosciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus Biosciences had 3 analyst reports since March 9, 2018 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Monday, May 14. The rating was maintained by Citigroup on Friday, March 9 with “Buy”. The stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) earned “Buy” rating by Maxim Group on Friday, March 9.

Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company has market cap of $1.26 billion. The firm engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It currently has negative earnings. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Nasdaq.com which released: “Market Trends Toward New Normal in United Technologies, Paychex, Coherus BioSciences, InfraREIT, Cousins …” on July 27, 2018, also Benzinga.com with their article: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” published on August 08, 2018, Nasdaq.com published: “Coherus BioSciences Announces New Employment Inducement Grants” on July 25, 2018. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Streetinsider.com and their article: “Pre-Open Stock Movers 7/18: (CHRS) (FNKO) (GWW) Higher; (SAH) (WIN) (HCSG) Lower (more…)” published on July 18, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Novartis Earnings, J&J’s HIV Combo Clears FDA Hurdle, Cara To Offer Shares” with publication date: July 18, 2018.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.